Phase 2 Trial of Cabozantinib (XL184), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Trial Profile

Phase 2 Trial of Cabozantinib (XL184), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Adrenal cancer; Ewing's sarcoma; Liver cancer; Nervous system neoplasms; Renal cell carcinoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Wilms' tumour
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 19 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top